MD667Z - Метод лечения инфекционного мононуклеоза у детей - Google Patents
Метод лечения инфекционного мононуклеоза у детейInfo
- Publication number
- MD667Z MD667Z MDS20130054A MDS20130054A MD667Z MD 667 Z MD667 Z MD 667Z MD S20130054 A MDS20130054 A MD S20130054A MD S20130054 A MDS20130054 A MD S20130054A MD 667 Z MD667 Z MD 667Z
- Authority
- MD
- Moldova
- Prior art keywords
- group
- treatment
- children
- patients
- therapy
- Prior art date
Links
- 201000006747 infectious mononucleosis Diseases 0.000 title claims abstract description 19
- 238000000034 method Methods 0.000 title claims abstract description 14
- 238000002560 therapeutic procedure Methods 0.000 claims abstract description 17
- 230000003115 biocidal effect Effects 0.000 claims abstract description 8
- 230000002443 hepatoprotective effect Effects 0.000 claims abstract description 6
- 239000011782 vitamin Substances 0.000 claims abstract description 6
- 229940088594 vitamin Drugs 0.000 claims abstract description 6
- 229930003231 vitamin Natural products 0.000 claims abstract description 6
- 235000013343 vitamin Nutrition 0.000 claims abstract description 6
- 150000003722 vitamin derivatives Chemical class 0.000 claims abstract description 4
- 235000012054 meals Nutrition 0.000 claims abstract description 3
- 238000001784 detoxification Methods 0.000 claims description 5
- 208000035473 Communicable disease Diseases 0.000 abstract description 6
- 239000003814 drug Substances 0.000 abstract description 2
- 210000004185 liver Anatomy 0.000 description 19
- BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 description 16
- 206010037660 Pyrexia Diseases 0.000 description 15
- 208000011580 syndromic disease Diseases 0.000 description 12
- QTCANKDTWWSCMR-UHFFFAOYSA-N costic aldehyde Natural products C1CCC(=C)C2CC(C(=C)C=O)CCC21C QTCANKDTWWSCMR-UHFFFAOYSA-N 0.000 description 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 11
- ISTFUJWTQAMRGA-UHFFFAOYSA-N iso-beta-costal Natural products C1C(C(=C)C=O)CCC2(C)CCCC(C)=C21 ISTFUJWTQAMRGA-UHFFFAOYSA-N 0.000 description 11
- 206010019842 Hepatomegaly Diseases 0.000 description 10
- 206010041660 Splenomegaly Diseases 0.000 description 9
- 201000010099 disease Diseases 0.000 description 9
- LELAOEBVZLPXAZ-UHFFFAOYSA-N iberin Chemical compound CS(=O)CCCN=C=S LELAOEBVZLPXAZ-UHFFFAOYSA-N 0.000 description 7
- 210000001165 lymph node Anatomy 0.000 description 7
- 210000004698 lymphocyte Anatomy 0.000 description 7
- 230000010352 nasal breathing Effects 0.000 description 7
- HYIMSNHJOBLJNT-UHFFFAOYSA-N nifedipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1[N+]([O-])=O HYIMSNHJOBLJNT-UHFFFAOYSA-N 0.000 description 7
- 210000000952 spleen Anatomy 0.000 description 6
- MGSRCZKZVOBKFT-UHFFFAOYSA-N thymol Chemical compound CC(C)C1=CC=C(C)C=C1O MGSRCZKZVOBKFT-UHFFFAOYSA-N 0.000 description 6
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 5
- 230000001154 acute effect Effects 0.000 description 5
- 208000015181 infectious disease Diseases 0.000 description 5
- 238000011835 investigation Methods 0.000 description 5
- 210000000265 leukocyte Anatomy 0.000 description 5
- 238000005259 measurement Methods 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 231100000331 toxic Toxicity 0.000 description 5
- 230000002588 toxic effect Effects 0.000 description 5
- 206010030094 Odynophagia Diseases 0.000 description 4
- 230000002146 bilateral effect Effects 0.000 description 4
- CVSVTCORWBXHQV-UHFFFAOYSA-N creatine Chemical compound NC(=[NH2+])N(C)CC([O-])=O CVSVTCORWBXHQV-UHFFFAOYSA-N 0.000 description 4
- 210000003743 erythrocyte Anatomy 0.000 description 4
- 230000001717 pathogenic effect Effects 0.000 description 4
- 230000000405 serological effect Effects 0.000 description 4
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 3
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 3
- 206010015108 Epstein-Barr virus infection Diseases 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 239000005844 Thymol Substances 0.000 description 3
- 239000003242 anti bacterial agent Substances 0.000 description 3
- 230000000840 anti-viral effect Effects 0.000 description 3
- 229940088710 antibiotic agent Drugs 0.000 description 3
- 238000004820 blood count Methods 0.000 description 3
- -1 by 4 cm Natural products 0.000 description 3
- 238000003759 clinical diagnosis Methods 0.000 description 3
- 235000005911 diet Nutrition 0.000 description 3
- 230000037213 diet Effects 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 206010024378 leukocytosis Diseases 0.000 description 3
- AEMBWNDIEFEPTH-UHFFFAOYSA-N n-tert-butyl-n-ethylnitrous amide Chemical compound CCN(N=O)C(C)(C)C AEMBWNDIEFEPTH-UHFFFAOYSA-N 0.000 description 3
- 238000002636 symptomatic treatment Methods 0.000 description 3
- 229960000790 thymol Drugs 0.000 description 3
- 206010044008 tonsillitis Diseases 0.000 description 3
- 208000004998 Abdominal Pain Diseases 0.000 description 2
- 206010067484 Adverse reaction Diseases 0.000 description 2
- 201000004813 Bronchopneumonia Diseases 0.000 description 2
- HZZVJAQRINQKSD-UHFFFAOYSA-N Clavulanic acid Natural products OC(=O)C1C(=CCO)OC2CC(=O)N21 HZZVJAQRINQKSD-UHFFFAOYSA-N 0.000 description 2
- 208000034657 Convalescence Diseases 0.000 description 2
- 108010034145 Helminth Proteins Proteins 0.000 description 2
- 102000001554 Hemoglobins Human genes 0.000 description 2
- 108010054147 Hemoglobins Proteins 0.000 description 2
- 102000007330 LDL Lipoproteins Human genes 0.000 description 2
- 108010007622 LDL Lipoproteins Proteins 0.000 description 2
- 206010025280 Lymphocytosis Diseases 0.000 description 2
- 206010027906 Monocytosis Diseases 0.000 description 2
- 206010067482 No adverse event Diseases 0.000 description 2
- 206010037596 Pyelonephritis Diseases 0.000 description 2
- 208000037656 Respiratory Sounds Diseases 0.000 description 2
- 102000003929 Transaminases Human genes 0.000 description 2
- 108090000340 Transaminases Proteins 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 206010047924 Wheezing Diseases 0.000 description 2
- 210000001015 abdomen Anatomy 0.000 description 2
- 230000003187 abdominal effect Effects 0.000 description 2
- 230000006838 adverse reaction Effects 0.000 description 2
- 229960003022 amoxicillin Drugs 0.000 description 2
- LSQZJLSUYDQPKJ-NJBDSQKTSA-N amoxicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=C(O)C=C1 LSQZJLSUYDQPKJ-NJBDSQKTSA-N 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 229940098164 augmentin Drugs 0.000 description 2
- 210000003651 basophil Anatomy 0.000 description 2
- 238000004159 blood analysis Methods 0.000 description 2
- 239000004202 carbamide Substances 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 229960003624 creatine Drugs 0.000 description 2
- 239000006046 creatine Substances 0.000 description 2
- 206010061428 decreased appetite Diseases 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 230000001079 digestive effect Effects 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 235000013601 eggs Nutrition 0.000 description 2
- 210000003979 eosinophil Anatomy 0.000 description 2
- 244000000013 helminth Species 0.000 description 2
- 208000006454 hepatitis Diseases 0.000 description 2
- 231100000283 hepatitis Toxicity 0.000 description 2
- 206010019847 hepatosplenomegaly Diseases 0.000 description 2
- 230000035987 intoxication Effects 0.000 description 2
- 231100000566 intoxication Toxicity 0.000 description 2
- 210000001616 monocyte Anatomy 0.000 description 2
- 210000005087 mononuclear cell Anatomy 0.000 description 2
- 238000010606 normalization Methods 0.000 description 2
- LSQZJLSUYDQPKJ-UHFFFAOYSA-N p-Hydroxyampicillin Natural products O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)C(N)C1=CC=C(O)C=C1 LSQZJLSUYDQPKJ-UHFFFAOYSA-N 0.000 description 2
- 210000002741 palatine tonsil Anatomy 0.000 description 2
- 230000002688 persistence Effects 0.000 description 2
- 230000013577 regulation of ventricular cardiomyocyte membrane repolarization Effects 0.000 description 2
- 230000033764 rhythmic process Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 238000002604 ultrasonography Methods 0.000 description 2
- RUDATBOHQWOJDD-UHFFFAOYSA-N (3beta,5beta,7alpha)-3,7-Dihydroxycholan-24-oic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)CC2 RUDATBOHQWOJDD-UHFFFAOYSA-N 0.000 description 1
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
- 239000004382 Amylase Substances 0.000 description 1
- 102000013142 Amylases Human genes 0.000 description 1
- 108010065511 Amylases Proteins 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 101000782236 Bothrops leucurus Thrombin-like enzyme leucurobin Proteins 0.000 description 1
- 206010057248 Cell death Diseases 0.000 description 1
- 229930186147 Cephalosporin Natural products 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 206010015993 Eyelid oedema Diseases 0.000 description 1
- 108020004206 Gamma-glutamyltransferase Proteins 0.000 description 1
- 206010019781 Hepatitis infectious mononucleosis Diseases 0.000 description 1
- 206010019799 Hepatitis viral Diseases 0.000 description 1
- 206010020565 Hyperaemia Diseases 0.000 description 1
- 206010068237 Hypertransaminasaemia Diseases 0.000 description 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
- 102000003855 L-lactate dehydrogenase Human genes 0.000 description 1
- 108700023483 L-lactate dehydrogenases Proteins 0.000 description 1
- 206010067125 Liver injury Diseases 0.000 description 1
- 208000008771 Lymphadenopathy Diseases 0.000 description 1
- ICKFFNBDFNZJSX-UHFFFAOYSA-N N'-[(4-chlorophenyl)methyl]-N,N-dimethyl-N'-(2-pyridinyl)ethane-1,2-diamine Chemical compound C=1C=CC=NC=1N(CCN(C)C)CC1=CC=C(Cl)C=C1 ICKFFNBDFNZJSX-UHFFFAOYSA-N 0.000 description 1
- SEBFKMXJBCUCAI-UHFFFAOYSA-N NSC 227190 Natural products C1=C(O)C(OC)=CC(C2C(OC3=CC=C(C=C3O2)C2C(C(=O)C3=C(O)C=C(O)C=C3O2)O)CO)=C1 SEBFKMXJBCUCAI-UHFFFAOYSA-N 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 206010033645 Pancreatitis Diseases 0.000 description 1
- 208000037273 Pathologic Processes Diseases 0.000 description 1
- 201000007100 Pharyngitis Diseases 0.000 description 1
- 206010041235 Snoring Diseases 0.000 description 1
- 206010041349 Somnolence Diseases 0.000 description 1
- 206010042682 Swelling face Diseases 0.000 description 1
- MKUXAQIIEYXACX-UHFFFAOYSA-N aciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCO)C=N2 MKUXAQIIEYXACX-UHFFFAOYSA-N 0.000 description 1
- 229960004150 aciclovir Drugs 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 235000019418 amylase Nutrition 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 230000001754 anti-pyretic effect Effects 0.000 description 1
- 229940125715 antihistaminic agent Drugs 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 239000002221 antipyretic Substances 0.000 description 1
- 229940125716 antipyretic agent Drugs 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 208000027119 bilirubin metabolic disease Diseases 0.000 description 1
- 238000009640 blood culture Methods 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 229940098900 cefotaxime 500 mg Drugs 0.000 description 1
- 229960004755 ceftriaxone Drugs 0.000 description 1
- VAAUVRVFOQPIGI-SPQHTLEESA-N ceftriaxone Chemical compound S([C@@H]1[C@@H](C(N1C=1C(O)=O)=O)NC(=O)\C(=N/OC)C=2N=C(N)SC=2)CC=1CSC1=NC(=O)C(=O)NN1C VAAUVRVFOQPIGI-SPQHTLEESA-N 0.000 description 1
- 229940124587 cephalosporin Drugs 0.000 description 1
- 150000001780 cephalosporins Chemical class 0.000 description 1
- 201000009058 cervical adenitis Diseases 0.000 description 1
- 208000012751 cervical lymphadenitis Diseases 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 229940084973 dexamethasone 4 mg Drugs 0.000 description 1
- 235000021004 dietary regimen Nutrition 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 229940030606 diuretics Drugs 0.000 description 1
- 208000017574 dry cough Diseases 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 102000006640 gamma-Glutamyltransferase Human genes 0.000 description 1
- 230000002489 hematologic effect Effects 0.000 description 1
- 231100000234 hepatic damage Toxicity 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 208000036796 hyperbilirubinemia Diseases 0.000 description 1
- 230000000544 hyperemic effect Effects 0.000 description 1
- 229960001680 ibuprofen Drugs 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 230000000286 interferogenic effect Effects 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 230000008818 liver damage Effects 0.000 description 1
- 208000018555 lymphatic system disease Diseases 0.000 description 1
- 201000004792 malaria Diseases 0.000 description 1
- 229960000282 metronidazole Drugs 0.000 description 1
- VAOCPAMSLUNLGC-UHFFFAOYSA-N metronidazole Chemical compound CC1=NC=C([N+]([O-])=O)N1CCO VAOCPAMSLUNLGC-UHFFFAOYSA-N 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 238000002559 palpation Methods 0.000 description 1
- 229960005489 paracetamol Drugs 0.000 description 1
- 230000009054 pathological process Effects 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- SEBFKMXJBCUCAI-HKTJVKLFSA-N silibinin Chemical compound C1=C(O)C(OC)=CC([C@@H]2[C@H](OC3=CC=C(C=C3O2)[C@@H]2[C@H](C(=O)C3=C(O)C=C(O)C=C3O2)O)CO)=C1 SEBFKMXJBCUCAI-HKTJVKLFSA-N 0.000 description 1
- 229960004245 silymarin Drugs 0.000 description 1
- 235000017700 silymarin Nutrition 0.000 description 1
- 239000008279 sol Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- RUDATBOHQWOJDD-UZVSRGJWSA-N ursodeoxycholic acid Chemical compound C([C@H]1C[C@@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)CC1 RUDATBOHQWOJDD-UZVSRGJWSA-N 0.000 description 1
- 229960001661 ursodiol Drugs 0.000 description 1
- 201000001862 viral hepatitis Diseases 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
Abstract
Изобретение относится к медицине, в частности к инфекционным болезням и может быть использовано для лечения инфекционного мононуклеоза у детей.Согласно изобретению, заявленный метод состоит в том, что назначают антибиотикотерапию, витаминотерапию, гепатопротекторную, дезинтоксикационную и симптоматическую терапию, а дополнительно применяют ежедневно, per os, за 30 мин до еды 5α-фуростан-3β,22,26-triol-3-[O-β-D-глукопиранозил(1→2)-β-D- глукопиранозил (1→4)-β-D-галактопиранозил]-26-O-β-D-глукопиранозид, по 50 мг, два раза в день, в течение 30 дней.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| MDS20130054A MD667Z (ru) | 2013-03-20 | 2013-03-20 | Метод лечения инфекционного мононуклеоза у детей |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| MDS20130054A MD667Z (ru) | 2013-03-20 | 2013-03-20 | Метод лечения инфекционного мононуклеоза у детей |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MD667Y MD667Y (en) | 2013-08-31 |
| MD667Z true MD667Z (ru) | 2014-03-31 |
Family
ID=49117539
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MDS20130054A MD667Z (ru) | 2013-03-20 | 2013-03-20 | Метод лечения инфекционного мононуклеоза у детей |
Country Status (1)
| Country | Link |
|---|---|
| MD (1) | MD667Z (ru) |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MD1875G2 (ru) * | 1999-11-01 | 2002-09-30 | Национальный Научно-Практический Центр Превентивной Медицины Министерства Здравоохранения Республики Молдова | Метод лечения острого вирусного гепатита В |
| MD2068G2 (ru) * | 2001-07-10 | 2003-06-30 | Национальный Научно-Практический Центр Превентивной Медицины Министерства Здравоохранения Республики Молдова | Метод лечения инфекции вируса простого герпеса |
| MD2549G2 (ru) * | 2003-07-18 | 2005-08-31 | Национальный Научно-Практический Центр Превентивной Медицины Министерства Здравоохранения Республики Молдова | Метод лечения хронического вирусного гепатита С |
| MD596Y (en) * | 2012-10-09 | 2013-02-28 | Ct Nat De Sanatate Publica Al Ministerului Sanatatii Al Republicii Moldova | Method for treating the chronic viral hepatitis C |
| MD4177C1 (ru) * | 2011-01-14 | 2013-02-28 | Национальный Центр Общественного Здоровья Министерства Здравоохранения Республики Молдова | Метод вакцинации против гепатита В лиц с иммунодефицитом |
-
2013
- 2013-03-20 MD MDS20130054A patent/MD667Z/ru not_active IP Right Cessation
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MD1875G2 (ru) * | 1999-11-01 | 2002-09-30 | Национальный Научно-Практический Центр Превентивной Медицины Министерства Здравоохранения Республики Молдова | Метод лечения острого вирусного гепатита В |
| MD2068G2 (ru) * | 2001-07-10 | 2003-06-30 | Национальный Научно-Практический Центр Превентивной Медицины Министерства Здравоохранения Республики Молдова | Метод лечения инфекции вируса простого герпеса |
| MD2549G2 (ru) * | 2003-07-18 | 2005-08-31 | Национальный Научно-Практический Центр Превентивной Медицины Министерства Здравоохранения Республики Молдова | Метод лечения хронического вирусного гепатита С |
| MD4177C1 (ru) * | 2011-01-14 | 2013-02-28 | Национальный Центр Общественного Здоровья Министерства Здравоохранения Республики Молдова | Метод вакцинации против гепатита В лиц с иммунодефицитом |
| MD596Y (en) * | 2012-10-09 | 2013-02-28 | Ct Nat De Sanatate Publica Al Ministerului Sanatatii Al Republicii Moldova | Method for treating the chronic viral hepatitis C |
Non-Patent Citations (1)
| Title |
|---|
| Rusu Galina, Galeţchi Axenia, Popovici Parascovia. Boli infecţioase la copii. Chişinău, 2012, p. 131-138 * |
Also Published As
| Publication number | Publication date |
|---|---|
| MD667Y (en) | 2013-08-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Chave et al. | Toxic epidermal necrolysis: current evidence, practical management and future directions | |
| Patil et al. | Prevalence of recurrent aphthous ulceration in the Indian Population | |
| Liang et al. | Mesenchymal stem cell transplantation for diffuse alveolar hemorrhage in SLE | |
| Niu et al. | Effects of Pinus massoniana pollen polysaccharides on intestinal microenvironment and colitis in mice | |
| CN104017746B (zh) | 乳杆菌、其组合物与用于制备治疗红斑性狼疮引起的心脏与肝脏病变的应用 | |
| Amjad et al. | Salivary antioxidant and oxidative stress marker levels in HIV-positive individuals | |
| Park et al. | Treatment of disseminated superficial actinic porokeratosis with oral alitretinoin. | |
| Santra et al. | Rosai-Dorfman disease | |
| MD667Z (ru) | Метод лечения инфекционного мононуклеоза у детей | |
| Keitel et al. | Nephrotic syndrome in congenital quartan malaria | |
| Bakke | Hepatic impairment during intake of contraceptive pills: Observations in post-menopausal women | |
| WO2021249402A1 (zh) | 无细胞脂肪提取液对巨噬细胞极化调节与疾病治疗的作用 | |
| EP1398036B1 (en) | Ganoderma lucidum spores for treatment of systemic lupus erytrhomatosus (SLE) | |
| Jafar et al. | Hypovitaminosis D in Hepatitis C patients and its relation with demographic and laboratory data | |
| Hasan et al. | The effect of melatonin on C-reactive protein, serum ferritin and D-dimer in COVID-19 patients | |
| CN117547587A (zh) | 一种预防和/或治疗艾滋病湿热证的中药组合物及其应用 | |
| Kudaravalli et al. | Acute on chronic immune thrombocytopenia as a cause of thrombocytopenia in sepsis | |
| Desai et al. | TREATMENT OF T-AYU-HM PREMIUM AND ONION STEAM VAPORISATION ON POSSIBLE RE-INFECTION OR REACTIVATION COVID-19 PATIENT: A CASE STUDY | |
| US11883418B2 (en) | Compound TSYI-ZAC for inhibiting dengue virus infection and medicinal use thereof | |
| MD596Z (ru) | Метод лечения хронического вирусного гепатита С у детей | |
| Gücüyener et al. | Suspected allergy to lamotrigine. | |
| Alebiosu et al. | Addison's disease: a case report | |
| Paul et al. | Scrub typhus along the Thai-Kampuchean border: new treatment regimen | |
| Nafi et al. | Management of a Case of Dengue Shock Syndrome with Liver Failure: A Case Report | |
| Desai et al. | Case Report Study of Integrated Treatment with T-AYU-HM Premium in a Child of Sickle Cell Disease: A 7 Year Follow up Study |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG9Y | Short term patent issued | ||
| KA4Y | Short-term patent lapsed due to non-payment of fees (with right of restoration) |